Form 6-K BioLineRx Ltd. For: Aug 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
August 11, 2016 11:46 AM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.
Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More
BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
August 11, 2016 7:19 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).
Expected upcoming significant milestones for remainder of 2016:
Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3... More